Literature DB >> 8807043

Fungal virulence genes as targets for antifungal chemotherapy.

J R Perfect1.   

Abstract

Fungal virulence genes have now met the age of molecular pathogenesis. The definition of virulence genes needs to be broad so that it encompasses the focus on molecular antifungal targets and vaccine epitopes. However, in the broad but simple definition of a virulence gene, there will be many complex genetic and host interactions which investigators will need to carefully define. Nevertheless, with the increasing numbers of serious fungal infections produced by old and newly reported organisms, the paucity of present antifungal drugs, and the likelihood of increasing drug resistance, the need for investigations into understanding fungal virulence at the molecular level has never been more important.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807043      PMCID: PMC163376     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  77 in total

1.  Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae.

Authors:  J H McCusker; K V Clemons; D A Stevens; R W Davis
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

2.  Virulence studies of Aspergillus nidulans mutants requiring lysine or p-aminobenzoic acid in invasive pulmonary aspergillosis.

Authors:  C M Tang; J M Smith; H N Arst; D W Holden
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

3.  Virulence of Aspergillus fumigatus double mutants lacking restriction and an alkaline protease in a low-dose model of invasive pulmonary aspergillosis.

Authors:  J M Smith; C M Tang; S Van Noorden; D W Holden
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

4.  HYP1, a hydrophobin gene from Aspergillus fumigatus, complements the rodletless phenotype in Aspergillus nidulans.

Authors:  M Parta; Y Chang; S Rulong; P Pinto-DaSilva; K J Kwon-Chung
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

5.  rodletless mutants of Aspergillus fumigatus.

Authors:  N Thau; M Monod; B Crestani; C Rolland; G Tronchin; J P Latgé; S Paris
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

6.  Molecular cloning and sequence analysis of yps-3, a yeast-phase-specific gene in the dimorphic fungal pathogen Histoplasma capsulatum.

Authors:  E J Keath; F E Abidi
Journal:  Microbiology       Date:  1994-04       Impact factor: 2.777

7.  Genetic characterization of pathogenic Saccharomyces cerevisiae isolates.

Authors:  J H McCusker; K V Clemons; D A Stevens; R W Davis
Journal:  Genetics       Date:  1994-04       Impact factor: 4.562

8.  A hyphal-specific chitin synthase gene (CHS2) is not essential for growth, dimorphism, or virulence of Candida albicans.

Authors:  N A Gow; P W Robbins; J W Lester; A J Brown; W A Fonzi; T Chapman; O S Kinsman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Acid proteinase secreted by Candida tropicalis: virulence in mice of a proteinase negative mutant.

Authors:  G Togni; D Sanglard; M Monod
Journal:  J Med Vet Mycol       Date:  1994

10.  Multiplicity of genes encoding secreted aspartic proteinases in Candida species.

Authors:  M Monod; G Togni; B Hube; D Sanglard
Journal:  Mol Microbiol       Date:  1994-07       Impact factor: 3.501

View more
  22 in total

Review 1.  Strategies for the identification of virulence determinants in human pathogenic fungi.

Authors:  R Alonso-Monge; F Navarro-García; E Román; B Eisman; C Nombela; J Pla
Journal:  Curr Genet       Date:  2003-02-08       Impact factor: 3.886

2.  Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Authors:  M Del Poeta; D L Toffaletti; T H Rude; C C Dykstra; J Heitman; J R Perfect
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

Review 3.  Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections.

Authors:  K W Deitsch; E R Moxon; T E Wellems
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

Review 4.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

5.  Identification of essential genes in the human fungal pathogen Aspergillus fumigatus by transposon mutagenesis.

Authors:  Arnaud Firon; François Villalba; Roland Beffa; Christophe D'Enfert
Journal:  Eukaryot Cell       Date:  2003-04

Review 6.  Potential role of phospholipases in virulence and fungal pathogenesis.

Authors:  M A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

7.  Impairment of p38 MAPK-mediated cytosolic phospholipase A2 activation in the kidneys is associated with pathogenicity of Candida albicans.

Authors:  Jung-Hwa Choi; Eun Kyoung Choi; Sung Jun Park; Hyun-Mi Ko; Kyoung-Jin Kim; Su-Ji Han; Il-Whan Choi; Suhn-Young Im
Journal:  Immunology       Date:  2006-10-20       Impact factor: 7.397

8.  Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.

Authors:  Peter Staib; Ulrich Lermann; Julia Blass-Warmuth; Björn Degel; Reinhard Würzner; Michel Monod; Tanja Schirmeister; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

9.  Characterization of essential genes by parasexual genetics in the human fungal pathogen Aspergillus fumigatus: impact of genomic rearrangements associated with electroporation of DNA.

Authors:  Arnaud Firon; Anne Beauvais; Jean-Paul Latgé; Elisabeth Couvé; Marie-Claire Grosjean-Cournoyer; Christophe D'Enfert
Journal:  Genetics       Date:  2002-07       Impact factor: 4.562

Review 10.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.